These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 3677116)

  • 1. Facilitation of emergence of multidrug-resistant state by alteration of tumor environment: implications from competitive ecology models.
    Michelson S
    Cancer Treat Rep; 1987 Nov; 71(11):1093-4. PubMed ID: 3677116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1979; 63(11-12):1727-33. PubMed ID: 526911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
    Buys TP; Chari R; Lee EH; Zhang M; MacAulay C; Lam S; Lam WL; Ling V
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1069-79. PubMed ID: 17726699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for multidrug-resistant cells in human tumor cell populations.
    Shoemaker RH; Curt GA; Carney DN
    Cancer Treat Rep; 1983 Oct; 67(10):883-8. PubMed ID: 6313186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT; Berek JS; Bonavida B
    Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modes of resistance to antitumor agents.
    Kessel D
    In Vivo; 1994; 8(5):829-34. PubMed ID: 7727732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular P-glycoprotein in multidrug resistant tumor cells.
    Arancia G; Molinari A; Calcabrini A; Meschini S; Cianfriglia M
    Ital J Anat Embryol; 2001; 106(2 Suppl 1):59-68. PubMed ID: 11729998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G; Waxman DJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
    Porter CW; Ganis B; Rustum Y; Wrzosek C; Kramer DL; Bergeron RJ
    Cancer Res; 1994 Nov; 54(22):5917-24. PubMed ID: 7954423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multidrug resistance (MDR)].
    Wada M; Hasegawa S; Kohno K; Kuwano M
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):936-44. PubMed ID: 8002631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
    Hanania EG; Deisseroth AB
    Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
    Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
    Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.